Bayer: Science For A Better Life

United States of America

Oncology Information for Grant Submissions

I. Background

Bayer Pharmaceuticals’ Medical Education department is committed to funding independent medical education initiatives that help to address important healthcare professional educational gaps and improve patient care.

II. General Information and Requirements

CFG Issue Date:

June 15, 2023

CFG Due Date:

June 15, 2023 – July 13, 2023

Initiation of Program Development:

Q3 2023

Therapeutic Area:

CNS tumors

  • Management and treatment of CNS cancers
  • Role of NTRK gene fusions and impact of TRK-fusion testing in treatment algorithms for local, regional and/or CNS cancers
  • Education on biomarker driven testing strategies/appropriate testing modalities
  • Multi-disciplinary approach to precision medicine
  • Understanding of efficacy and safety profiles of approved TRK inhibitors in local, regional and/or CNS cancers

Type of Initiative:

Online and/or print educational activities

Activity Format Examples:

  • Online stand-alone program - preferred
  • Grand rounds program + enduring materials
  • Podcast + enduring materials

Primary Target Audience

Oncologists, Community HCPs, Surgeons, Pathologists

Geographic Scope:

United States

Expected Monetary Range

$50,000 - $100,000.00

How to Submit:

1. Review Bayer Pharmaceuticals Grant Guidelines:

2. Review additional CFG requirements outlined within this document

3. Submit via Bayer Pharmaceuticals’ online request form:

NOTE: Please reference ‘CNS CFG’ in the title.


Questions may be submitted to (please reference ‘CNS CFG’)

Notification Process:

Upon Grant Review Committee evaluation and assessment, the requestor is notified of the decision via e-mail to the address entered on the Grant Request Form

III. Proposal Requirements

  1. Formal letter of request, including:
    1. Program title
    2. Brief Program Outline/description
    3. Program development start date
    4. Target release date of program (if applicable)
    5. Rationale and approach to program placement (if applicable)
    6. Anticipated attendance and breakdown by specialty (if applicable)
    7. Amount requested
    8. CME credits offered
  2. Needs Assessment
  3. Learning Objectives and Educational Gaps: specific, measurable, performance based.
  4. Target Audience and Audience Generation: describe the target audience(s) and provide a rationale for how and why this target audience is important to closing the identified healthcare gap. Additionally, describe methods of reaching the target audience(s) including description and rationale for recruitment strategies.
  5. Educational Method and Design: considers appropriate target audience and learning preferences.
  6. Venue (if applicable): describe target venue (i.e., distribution amongst academic institutions, large community hospitals and networks, and others).
  7. Meeting Placement Strategy and Institution Vetting Process (if applicable)
  8. Delivery Format: describe rationale of delivery format
  9. Potential Faculty
  10. Faculty Recruitment and Training Strategy
  11. Program Development Timeline
  12. Program Agenda
  13. Program Budget: detailed budget with rationale including breakdown of costs with clear calculations.
  14. Educational Outcomes: provide a description of the approach to evaluate the reach and quality of program delivery (minimum outcomes: Moore’s levels 1-4).
  15. Communication/Activity Update Plan (optional)
  16. Completed, recent W-9 form

IV. Compliance: grant application must be compliant with ACCME guidelines, free of commercial bias/influence, non-promotional, and fair balanced.

V. Terms and Conditions

  1. This CFG does not commit Bayer Pharmaceuticals to award a grant or to pay any costs incurred in the preparation of this request.
  2. Bayer Pharmaceuticals reserves the right to accept or reject any or all applications received as a result of this request or to cancel in part or in its entirety this CFG at any time without prior notification or permission.
  3. The grant application must be submitted via Bayer Pharmaceuticals’ online request form
  4. All communications about the CFG must come exclusively to Bayer Pharmaceuticals Medical Education,


Management and treatment of CNS cancers

  1. NIH – Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: Brain and Other Nervous System Cancer.(link)
  2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2019 – September 16, 2019 (link)

Diagnosis, treatment and management of TRK fusion cancer

  1. Nagasubramanian R, Wei J, Gordon P, Rastatter JC et al. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. (link)
  2. Hong DS, Bauer TM, Lee JJ et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1;30(2):325-331. (link)
  3. Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family protein in cancer. Pharmacol Ther 2017 (173), 58-66. (link)
  4. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
  5. Cocco, E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (link)
  6. Hyman, DM et al. Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer. Annals of Oncology 30 (5), October 2019 (link)
  7. Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (link)
  8. Ricciuti, B et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019 Apr 30;12:3171-3179 (link)
  9. Solomon, JP et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019 Aug 2. (Epub ahead of print) (link)
  10. Wong, D et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019 Jun 29. (Epub ahead of print) (link)
  11. Drilon, AE et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. Journal of Clinical Oncology 37, 2019 (suppl; abstr 2006) (link)
  12. Ziegler DS, Wong M, Mayoh C et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018 Sep;119(6):693-696. (link)
  13. WWalter, AW et al. Larotrectinib imaging response in low-grade glioma. Pediatr Blood Cancer. 2020 Jan;67(1):e28002(link)
  14. Perreault, S. et al. Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumors. ASCO 2021 abstract.()
  15. Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022 Jun 1;24(6):997-100. (link)
  16. Perreault, S. et al. Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors. ASCO 2022 abstract.(link)